Comparative Efficacy of Twice and Thrice Daily Colistin Administration in Critically Ill Patients Battling Multi-Drug Resistant Gram-Negative Infections: An Observational Study
Journal of Medical Microbiology and Infectious Diseases · 2024
DOI: 10.61186/jommid.12.1.50 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology and Infectious Diseases, 2024. Verfasst von Mohammed Valiyakath Hydross und 3 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Colistin, a polymyxin antibiotic often reserved for treatment of multidrug-resistant Gram-negative infections, exhibits a narrow therapeutic index.Careful consideration of the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of colistin is essential to maximize its efficacy and minimize toxicity.Both thrice-daily and twice-daily administration regimens have been employed, with critically ill patients posing unique challenges regarding colistin's PK/PD.
Methods
This retrospective observational study compared the mortality rates, cure rates, length of hospital stay, nephrotoxicity, and readmission rates associated with thrice-daily and twice-daily administration of a fixed total daily dose of 9 million international units (MIU) of colistin in 151 critically ill patients with multidrug-resistant Gram-negative infections.Propensity score matching with a 1:5 case-control ratio was performed using XLSTAT software (by Addinsoft), and outcomes were analysed using logistic regression analysis.
Results
Thrice-daily dosing of colistin was recorded in 125 patients, and twice-daily dosing in 26 patients.A total of 73 patients were included in the final analysis after propensity score matching.The 28-day mortality rates, clinical cure rates, and microbiological failure rates were comparable between the two groups (Odds ratio (OR) [95% confidence-interval (CI)] = 0.48 [0.07-3.46],P=0.467; 1.67 [0.31-8.90],P=0.548; 0.13 [0.001-19.5],P = 0.428, respectively).Hospital readmission rates within 90 days (OR [95% CI] = 1.05 [0.12-9.10],P=0.964) and duration of hospital stay (Beta coefficient = 1.55,P=0.683) were also comparable between the two groups.The incidence of nephrotoxicity-related AKI events during Colistin therapy was significantly lower with the 4.5 MIU twice-daily regimen (OR [95% CI] = 0.04 [0.004-0.35],P=0.004).
Conclusion
Twice-daily colistin administration significantly reduces the risk of nephrotoxicity-related AKI events compared to thrice-daily administration in critically ill patients with multidrug-resistant Gram-negative infections.
Zitieren
APA
Hydross, M. V., Samad, S. A., Savitri, M. B., & Upadhyay, A. D. (2024). Comparative Efficacy of Twice and Thrice Daily Colistin Administration in Critically Ill Patients Battling Multi-Drug Resistant Gram-Negative Infections: An Observational Study. Journal of Medical Microbiology and Infectious Diseases. https://doi.org/10.61186/jommid.12.1.50
Vancouver
Hydross MV, Samad SA, Savitri MB, Upadhyay AD. Comparative Efficacy of Twice and Thrice Daily Colistin Administration in Critically Ill Patients Battling Multi-Drug Resistant Gram-Negative Infections: An Observational Study. Journal of Medical Microbiology and Infectious Diseases. 2024. doi:10.61186/jommid.12.1.50
BibTeX
@article{Hydross2024,
author = {Hydross, Mohammed Valiyakath and Samad, Sameer Abdul and Savitri, Mahesh Balakrishna and Upadhyay, Ashish Datt},
title = {Comparative Efficacy of Twice and Thrice Daily Colistin Administration in Critically Ill Patients Battling Multi-Drug Resistant Gram-Negative Infections: An Observational Study},
journal = {Journal of Medical Microbiology and Infectious Diseases},
year = {2024},
doi = {10.61186/jommid.12.1.50}
}
EUVIMED